Form D · Biotechnology
Promisight, Inc.
Palo Alto, CA · CIK 0001729899
Offering snapshot reported Feb 1, 2018 · SEC filing
- Reported sold
- $250K Indefinite offering
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Dec 20, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 1, 2018 | Initial | $250,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-304564
Does not include $50,000 sold to an investor resident in a foreign country.
Source: Form D, filed Feb 1, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ori Braun | Director, Executive |
| Darius M. Moshfeghi | Director |
| Martin G. O'toole | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
237 Washington Ave
Palo Alto, CA, 94301
Palo Alto, CA, 94301